Aug 13, 2020
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Sep 29, 2019
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Sep 19, 2019
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Aug 22, 2019
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study
May 20, 2019
Kazia Enters Clinical Collaboration for Metastatic Brain Cancer with Alliance for Clinical Trials in Oncology
Oct 19, 2018
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
Jan 08, 2018
MEI Pharma Announces FDA Clearance of Investigational New Drug Application for CDK Inhibitor Voruciclib
Dec 21, 2017
MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
Nov 27, 2017
World Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis 2017 - Approximately 24 Drug Candidates in Different Stages of Development
Nov 16, 2017
Global Cancer CDK Inhibitors Market & Clinical Pipeline 2017-2022 - $20 Billion Market Opportunity Assessment
Nov 14, 2017
Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics - Pipeline Analysis 2017
Sep 05, 2017
MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor